Bharat Biotech refused to supply 67 lakh doses of Covaxin to Delhi on Centre’s directives: Dy CM Manish Sisodia


Bharat Biotech has refused to deliver the required doses of its Covid-19 vaccine Covaxin to Delhi, Deputy Prime Minister Manish Sisodia claimed on Wednesday. Speaking at a press conference, Sisodia said Delhi has requested a total of 1.34 crore doses of two Covid vaccines – 67 lakhs each from Covaxin and Covishield. However, Bharat Biotech informed the Delhi government of its inability to deliver the said doses as it is “shipping according to instructions from concerned government officials”.

Sisodia claimed it was evident that Bharat Biotech was talking about central government officials.

“They continued:” We sincerely regret that we cannot make additional deliveries based on your requests. “I don’t know how much is being delivered to other states, but they wrote us that they cannot supply Delhi because they have to supply according to the central government regulation,” said the deputy CM.

Manish Sisodia said Delhi had run out of vaccines.

“Our reserves are exhausted. The centers that give Covishield vaccines are working, but we had to close the centers that give Covaxin. As a result, we had to close more than 100 centers in 17 schools,” said Sisodia.

The deputy prime minister and AAP chairman called on the center to stop all vaccine-related exports and allow more companies to manufacture the cans.

“The center should act as the government of a country. They should meet their responsibilities and stop all exports,” he said.

Sisodia also said the center must import doses of vaccine from around the world and make them available to state governments. “Importing and supplying vaccines to state governments should be the responsibility of the center. State governments should be responsible for ensuring that vaccination runs smoothly and quickly,” he said.

As part of the national vaccine policy, the center is responsible for the vaccination campaign for all adults over 45 years of age. For the 18- to 44-year-old age group, the state governments were asked to purchase the vaccines directly from national or international vendors. However, domestic manufacturers – the Serum Institute of India and Bharat Biotech – are required to sell at least 50 percent of their inventory to the center, while the rest can be sold to both states and health facilities.




Post a Comment

और नया पुराने